Skip to main content
. 2018 Oct 3;144(5):981–990. doi: 10.1002/ijc.31751

Figure 3.

Figure 3

Disease‐specific survival (DSS) since start of first‐line therapy of patients with LAPC/MPC. DSS of (a) the whole TPK cohort (n = 1,174), (b) of the patients receiving gemcitabine monotherapy (n = 272), (c) of the patients receiving nab‐paclitaxel plus gemcitabine (n = 489), and (d) of the patients receiving FOLFIRINOX (n = 284). Abbreviations: CI, confidence interval; DSS, disease‐specific survival.